Novo Signs $1.4B Orbis Deal to Build Oral Macrocyclic Peptides
Novo and Orbis Medicines will co-discover oral macrocyclic peptides for unnamed cardiometabolic targets, with Orbis eligible for up to $1.4 billion plus royalties.
Novo and Orbis Medicines will co-discover oral macrocyclic peptides for unnamed cardiometabolic targets, with Orbis eligible for up to $1.4 billion plus royalties.